Clinical trials: TACE(Transcatheter Arterial Chemoembolization)
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Carcinoma, Hepatocellular
Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)
Most HCC patients are diagnosed at advanced stages in Korea, transcatheter arterial chemoembolization is considered a key modality for palliative treatment in these HCC patients.
- Trial name
- NCT00919009
- Testing
- TACE (Transcatheter Arterial Chemoembolization )
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Transarterial Chemoembolization, Hepatocellular Carcinoma
TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
Purpose：explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
- Trial name
- OXRI (NCT04597970)
- Testing
- cTACE-HAIC
- Volunteers
- 66 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular…
- Trial name
- NCT06602011
- Testing
- TACE, Lenvatinib, combined with Tislelizumab group
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma, Hepatic Chemotherapy
TACE Combined Surgery for the Resectable Huge HCC
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular…
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
- Trial name
- NCT06898398
- Testing
- TACE, Surgery
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating spinal cord NMDA receptor(N-methyl-D-aspartic…
- Conditions
- Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Pain
- Trial name
- TACE-HAIC (NCT05416073)
- Testing
- Esketamine, Sufentanil
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
- Trial name
- NCT06740370
- Testing
- TACE, Lenvatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cancer
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
The purpose of this study is to prospectively evaluate whether transcatheter arterial chemoembolization (TACE) will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.
- Trial name
- TACE-RFA (NCT00556803)
- Testing
- radiofrequency ablation, TACE after RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma…
- Trial name
- NCT05171335
- Testing
- Lenvatinib, Transcatheter Arterial Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
Colorectal Adenocarcinoma Metastatic to the Liver
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in…
- Trial name
- NCT03783559
- Testing
- TACE, chemotherapy±target therapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Portal Vein Occlusion
TACE Combined With Iodine-125 Seeds Implantation for HCC
Portal vein tumour thrombus (PVTT) is a common complication of hepatocellular carcinoma (HCC). PVTT has a profound adverse effect on prognosis, with a very short median survival time (2-4 months).
- Conditions
- Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus
- Trial name
- NCT03322280
- Testing
- TACE combined with iodine-125 seeds implantation, TACE
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization)
Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE
This randomized controlled trial aims to evaluate the effectiveness of enhanced web-based health education on self-care practices and quality of life among patients with hepatocellular carcinoma.
- Conditions
- Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of Life
- Trial name
- NCT07825519
- Testing
- Enhanced Web-Based Health Education, Routine Health Education
- Where
- Vietnam
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.
- Trial name
- NCT02631499
- Testing
- TACE, Epirubicin, lipiodol
- Where
- 6 sites in China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC)…
- Trial name
- TACE (NCT04569799)
- Testing
- Lumason
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Milton S. Hershey Medical Center
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- TACTICS (NCT01217034)
- Testing
- TACE with sorafenib, TACE alone
- Where
- Japan
- Volunteers
- 228 people
- Sponsor
- Kindai University
Hepatocellular Carcinoma
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved.
- Trial name
- TACEHCC (NCT00646100)
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.
- Trial name
- TACE+RFA (NCT03636620)
- Testing
- Transcatheter arterial chemoembolization, radiofrequency ablation/microwave ablation
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Fudan University
Large HCC Patients, Stereotactic Body Radiation Therapy
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The…
- Conditions
- Large HCC Patients, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
- Trial name
- NCT04512846
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital